IR@PKUHSC  > 北京大学基础医学院  > 细胞生物学系
学科主题基础医学
Analysis of CD137L and IL-17 Expression in Tumor Tissue as Prognostic Indicators for Gliblastoma
Cui, Xiangli1,2; Xu, Zhiqin3; Zhao, Zhigang2; Sui, Dali1; Ren, Xiaohui1; Huang, Qiming4; Qin, Jiazhen5; Hao, Limin4; Wang, Zhenguang4; Shen, Li6,7; Lin, Song1
关键词CD137L Interleukin-17 glioblastoma overall survival
刊名INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
2013
DOI10.7150/ijbs.4891
9期:2页:134-141
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biochemistry & Molecular Biology ; Biology
研究领域[WOS]Biochemistry & Molecular Biology ; Life Sciences & Biomedicine - Other Topics
关键词[WOS]T-CELLS ; 4-1BB LIGAND ; IN-VIVO ; CANCER ; GLIOBLASTOMA ; LYMPHOCYTES ; SURVIVAL ; PROMOTES ; GLIOMA
英文摘要

Glioblastoma multiforme (GBM) is the most common form of malignant glioma, characterized by genetic instability and unpredictable clinical behavior. GBM is marked by an extremely poor prognosis with median overall survival of 12 similar to 14 months. In this study, we detected the CD137L-expressing cells and IL-17-expressing cells in tumor tissues resected from patients with GBM. Expression of CD137L and IL-17 were assessed by immunohistochemistry, and the prognostic value of CD137L and IL-17 expression within the tumor tissues were assessed by Cox regression and Kaplan-Meier analysis. Immunohistochemical detection showed that positive cells of CD137L and IL-17 in glioblastoma tissue samples were 46.3% (19/41) and 73.2% (30/41) respectively. Expression of CD137L was not correlated with overall survival of GBM patients (P=0.594), while significantly longer survival rate was seen in patients with high expression of IL-17, compared to those with low expression of IL-17 (P=0.007). In addition, we also found that IL-17 expression was significantly correlated with Progression-free survival (PFS) (P=0.016) and death rate (P=0.01). Furthermore, multivariate Cox proportional hazard analyses revealed that IL-17 (P=0.018) and PFS (P=0.028) were independent factors affecting the overall survival probability. Kaplan-Meier analysis showed that PFS of high expression of IL-17 group were significantly longer (P=0.004) than low expression group with GBM. It is concluded that high levels of IL-17 expression in the tumor tissues may be a good prognostic marker for patients with GBM.

语种英语
WOS记录号WOS:000315565900001
项目编号7122061
资助机构Beijing Natural Science Foundation
引用统计
被引频次:14[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/61664
专题北京大学基础医学院_细胞生物学系
北京大学基础医学院
作者单位1.Beijing Cellonis Biotechnol Co Ltd, Beijing 100085, Peoples R China
2.Peking Univ, Stem Cell Res Ctr, Beijing 100091, Peoples R China
3.Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China
4.Capital Med Univ, Beijing Tiantan Hosp, Dept Pharm, Beijing 100050, Peoples R China
5.Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Neurosurg, Beijing 100730, Peoples R China
6.Beijing PLA, Mil Gen Hosp, Affiliated Bayi Brain Hosp, Beijing 100700, Peoples R China
7.Peking Univ, Hlth Sci Ctr, Dept Cell Biol, Beijing 100091, Peoples R China
推荐引用方式
GB/T 7714
Cui, Xiangli,Xu, Zhiqin,Zhao, Zhigang,et al. Analysis of CD137L and IL-17 Expression in Tumor Tissue as Prognostic Indicators for Gliblastoma[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES,2013,9(2):134-141.
APA Cui, Xiangli.,Xu, Zhiqin.,Zhao, Zhigang.,Sui, Dali.,Ren, Xiaohui.,...&Lin, Song.(2013).Analysis of CD137L and IL-17 Expression in Tumor Tissue as Prognostic Indicators for Gliblastoma.INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES,9(2),134-141.
MLA Cui, Xiangli,et al."Analysis of CD137L and IL-17 Expression in Tumor Tissue as Prognostic Indicators for Gliblastoma".INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES 9.2(2013):134-141.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Cui, Xiangli]的文章
[Xu, Zhiqin]的文章
[Zhao, Zhigang]的文章
百度学术
百度学术中相似的文章
[Cui, Xiangli]的文章
[Xu, Zhiqin]的文章
[Zhao, Zhigang]的文章
必应学术
必应学术中相似的文章
[Cui, Xiangli]的文章
[Xu, Zhiqin]的文章
[Zhao, Zhigang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。